Molecular basis of obesity and the risk for cardiovascular disease

被引:6
作者
Soufi, Muhidien [1 ]
Sattler, Alexander M. [1 ]
Herzum, Matthias [1 ]
Maisch, Bernhard [1 ]
Schaefer, Juergen R. [1 ]
机构
[1] Univ Marburg, Univ Hosp Giessen, Dept Internal Med Cardiol Angiol & CAD Prevent, Marburg, Germany
关键词
obesity; lipids; metabolic syndrome; gene variants; cardiovascular risk factors;
D O I
10.1007/s00059-006-2801-2
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Atherosclerosis and cardiovascular disease (CVD) are the main causes of death in the Western world, for both men and women. The onset and development of diseases of the cardiovascular and cerebrovascular system are strongly dependent on multiple risk factors that promote pathologic conditions like atherosclerosis, hypertension and thrombosis. Besides genetic factors also environmental influences such as diet composition are known to be closely related to CVD. In this context obesity has been postulated as an independent cardiovascular risk factor. Data from the Framingham Heart Study have consistently shown that increasing degrees of obesity are accompanied by greater rates of CVD. At present, obesity affects 10-35% of the European and US population and increases steadily. As obesity is a serious health problem which promotes metabolic abnormalities (insulin resistance, hyperinsulinemia and dyslipidemia) and dramatically increases the risk for CVD, this review will focus on the epidemiologic and genetic background of obesity. Furthermore, the molecular mechanisms involved in obesity development and their contribution to CVD will be discussed.
引用
收藏
页码:200 / 206
页数:7
相关论文
共 59 条
[1]
[Anonymous], WORLD HLTH REP 2001
[2]
Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity [J].
Arita, Y ;
Kihara, S ;
Ouchi, N ;
Takahashi, M ;
Maeda, K ;
Miyagawa, J ;
Hotta, K ;
Shimomura, I ;
Nakamura, T ;
Miyaoka, K ;
Kuriyama, H ;
Nishida, M ;
Yamashita, S ;
Okubo, K ;
Matsubara, K ;
Muraguchi, M ;
Ohmoto, Y ;
Funahashi, T ;
Matsuzawa, Y .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1999, 257 (01) :79-83
[3]
ATHEROGENIC LIPOPROTEIN PHENOTYPE - A PROPOSED GENETIC-MARKER FOR CORONARY HEART-DISEASE RISK [J].
AUSTIN, MA ;
KING, MC ;
VRANIZAN, KM ;
KRAUSS, RM .
CIRCULATION, 1990, 82 (02) :495-506
[4]
Gut hormone PYY3-36 physiologically inhibits food intake [J].
Batterham, RL ;
Cowley, MA ;
Small, CJ ;
Herzog, H ;
Cohen, MA ;
Dakin, CL ;
Wren, AM ;
Brynes, AE ;
Low, MJ ;
Ghatei, MA ;
Cone, RD ;
Bloom, SR .
NATURE, 2002, 418 (6898) :650-654
[5]
Blundell JE, 2000, BRIT J NUTR, V83, pS33
[6]
Physical activity efficacy and effectiveness among older adults and minorities [J].
Clark, DO .
DIABETES CARE, 1997, 20 (07) :1176-1182
[7]
Leptin and the control of metabolism: Role for stearoyl-CoA desaturase-1 (SCD-1) [J].
Cohen, P ;
Friedman, JM .
JOURNAL OF NUTRITION, 2004, 134 (09) :2455S-2463S
[8]
HIGH-DENSITY-LIPOPROTEIN CHOLESTEROL CONCENTRATIONS AND POSTHEPARIN HEPATIC AND LIPOPROTEIN LIPASES IN OBESITY - RELATIONSHIPS WITH PLASMA-INSULIN LEVELS [J].
COMINACINI, L ;
GARBIN, U ;
DAVOLI, A ;
CAMPAGNOLA, M ;
DESANTIS, A ;
PASINI, C ;
PASTORINO, AM ;
BOSELLO, O .
ANNALS OF NUTRITION AND METABOLISM, 1993, 37 (04) :175-184
[9]
Stearoyl-CoA desaturase as a new drug target for obesity treatment [J].
Dobrzyn, A ;
Ntambi, JM .
OBESITY REVIEWS, 2005, 6 (02) :169-174
[10]
ECKEL RH, 1995, INT J OBESITY, V19, pS16